The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells

可通过在CD34+祖细胞中连续监测伴有del(5q)缺失的骨髓增生异常综合征患者对来那度胺的反应。